MaaT Pharma to Present Preclinical Data

at SITC on MaaT034, an Artificial Intelligence-Generated Product Aimed at Improving Patients’ Responses to Immunotherapies.

Presentation of AI-based screening strategy developed to identify a new generation of drug candidates, MaaT034 being the first product from the new range.
First-time presentation of in vitro data for MaaT034, a new generation product, demonstrating biological activity that enhanced responses to Immune Checkpoint Inhibitors (ICIs) therapies.